NASDAQ · PDSB
PDS Biotechnology Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PDSB: Nov 12, 2026
PDS Biotechnology Corporation Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.11. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.11 | $-0.10 | $-0.11 | 2 |
| Dec 2026 | $-0.09 | $-0.09 | $-0.09 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · Zacks · RTTNews · The Motley Fool- MarketBeat · Oct 15, 9:02 PM EDTPDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerPDS Biotechnology (NASDAQ:PDSB) outlined plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases, following discussions with the U.S. Food and Drug Administration and clinical fin
- Zacks · Oct 14, 11:00 AM EDTPDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Sep 15, 2:43 PM EDTBiotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers(RTTNews) – Several biotech stocks were in focus Tuesday, including PDS Biotech following a potential $22.55 million PIPE financing; Avaí Bio after completing testing of its GMP Master Cell Bank; Clene following a $4 million registered direct offering; NurExone after entering an
- RTTNews · Sep 8, 2:43 PM EDT5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara(RTTNews) – Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3 CHAPTER-3 results; Roivant following positive Phase 2 PHocus data; PDS Biotech afte
- RTTNews · Sep 8, 11:42 AM EDTPDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong(RTTNews) – PDS Biotechnology Corporation (PDSB) announced an equity financing of up to $22.55 million in a private investment in public equity (PIPE) transaction led by Nant Capital, LLC, with participation from existing investors.
- RTTNews · Aug 11, 12:50 PM EDTPDS Biotech Refocuses On PDS0301 In Colorectal Cancer; Seeks Partners For PDS0101(RTTNews) – PDS Biotechnology Corporation (PDSB), a late-stage immunotherapy company focused on developing targeted cancer therapies, announced a strategic refocus of its development portfolio, with investors focusing on the advancement of PDS0301 in metastatic colorectal cancer
- Zacks · Jun 10, 9:55 AM EDTHere's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom FisherPDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a
- The Motley Fool · May 27, 5:33 PM EDTPDSB Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 13, 2:51 PM EDTPDSB Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 13, 2:09 PM EDTPDS Biotechnology Q1 Earnings Call HighlightsPDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executiv
- RTTNews · Apr 17, 10:38 AM EDTWeekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Colorectal Cancer, Obesity and Fatty Liv
- BNK Invest · Apr 16, 12:10 PM EDTThursday Sector Laggards: Drugs, Biotechnology StocksIn trading on Thursday, drugs shares were relative laggards, down on the day by about 1%. Helping drag down the group were shares of PDS Biotechnology, down about 10.3% and shares of Akebia Therapeutics off about 9.4% on the day. Also lagging the market Thursday are biotechnol
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for PDS Biotechnology Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.